Clinical Trial Search

Primary: The Proportion of Participants With Eradication of Gardnerella Vaginalis (GV) in Each Study Arm at Visit 2 (Day 15-21) as Assessed by Nucleic Acid Amplification Test…

Primary: Recurrent Bacterial Vaginosis — 7; 7 Participants — p=0.75

Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 68; 25 Participants — p=<0.001

Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 59; 19 Participants — p=<0.001

Primary: The Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) in Each Study Arm. — 0.11; 0.07 proportion of…

Primary: Number of Patients With Bacterial Vaginosis at 3 Months — 15; 16 Participants

Primary: Number of Participants With Related Clinical Signs or Symptoms at Baseline — 63; 63 Participants — p=<0.01

Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 18 Participants — p=<0.001

Primary: Number of Participants With Clinical Cure in Each Study Arm — 11; 8 Participants — p=0.420

Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…

Primary: Cure of Bacterial Vaginosis — 75; 73; 77 participants

Primary: Clinical Cure Rate — 18 Participants

Primary: Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria — 7.53; 2.04; 3.36; 3.35 Incidence: events per PY at risk

Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001

Primary: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment — 67.1; 79.2; 32.9; 20.8 Percentage of Participants

Primary: Percentage of Participants Cured of Vaginal Trichmonas — 90; 90; 88 percentage of participants

Primary: Number of Women With Clinical Cure as a Measure of Efficacy — 7; 12; 7; 3 Participants — p=0.006

Primary: Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit — 275; 268; 27; 41…

Primary: Clinical Outcome Responder Rate — 57; 11; 50; 46 Participants

Primary: Cure of Bacterial Vaginosis — 33; 42; 11; 31 Participants

Primary: Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings — 130; 158 Participants — p=0.015

Primary: Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit — 31; 29; 43 Participants — p=0.030

Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants

Primary: Proportion of Participants With Recurrent Bacterial Vaginosis (RBV) by Visit 4, as Defined by Presence of at Least 3 Amsel Criteria — 0.581; 0.697 proportion of…

Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…

Primary: Number of Subjects With at Least One Episode of Bacterial Vaginosis — 8 Participants

Primary: Number of Female Partners Whose Male Partners Received Metronidazole Versus Females Whose Male Partners Did Not Receive Metrodiazole With Recurrence of BV in the Female…

Primary: Clinical Cure — 135; 129; 74 Participants — p=<0.001

Primary: TV Culture Positive Result — 11; 21 participants — p=.045

Primary: Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score. — 1.13; 1.21; 0.18; 0.22 score on a scale